Kindred Biosciences Inc. received the first U.S. approval for a treatment for unintended weight loss in cats.
Heavy drinkers may be more likely than other adults to develop dementia, especially in middle age, a French study suggests.
A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.
Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.
Auris Medical Holding’s HEALOS Phase III clinical trial of AM-111 for acute inner ear hearing loss failed to meet its primary endpoint.
Otonomy announced the success of its AVERTS-2 Phase III clinical trial of Otividex in patients with Meniere’s disease.
Otonomy is cutting jobs and slashing operations in order to stay in business.
Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.
The U.S. Food and Drug Administration approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).
Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.